Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIC: Solifenacin for Neurogenic Detrusor Overactivity
NCT00629642Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2008
- Primary completion
- Jan 2011
- Modality
- Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 4 trial of solifenacin in neurogenic detrusor overactivity (NDO), sponsored by Astellas Pharma. Started Mar 2008; status: completed.
02
Drugs
solifenacin
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT00629642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00629642.